Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugate

Blood Adv. 2022 Nov 22;6(22):5933-5937. doi: 10.1182/bloodadvances.2022008503.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents*
  • Child
  • Folate Receptor 1
  • Humans
  • Immunoconjugates* / pharmacology
  • Immunoconjugates* / therapeutic use
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics

Substances

  • Immunoconjugates
  • Antineoplastic Agents
  • FOLR1 protein, human
  • Folate Receptor 1